As of 2024-12-14, the EV/EBITDA ratio of Hikma Pharmaceuticals PLC (HIK.L) is 5.55. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. HIK.L's latest enterprise value is 5,252.90 mil GBP. HIK.L's TTM EBITDA according to its financial statements is 946.00 mil GBP. Dividing these 2 quantities gives us the above HIK.L EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 6.3x - 8.4x | 7.3x |
| Forward P/E multiples | 12.0x - 16.9x | 14.4x |
| Fair Price | 1,709.09 - 3,439.33 | 2,444.24 |
| Upside | -12.5% - 76.0% | 25.1% |
| Date | EV/EBITDA |
| 2024-12-13 | 5.81 |
| 2024-12-12 | 5.81 |
| 2024-12-11 | 5.84 |
| 2024-12-10 | 5.82 |
| 2024-12-09 | 5.82 |
| 2024-12-06 | 5.76 |
| 2024-12-05 | 5.78 |
| 2024-12-04 | 5.82 |
| 2024-12-03 | 5.83 |
| 2024-12-02 | 5.77 |
| 2024-11-29 | 5.74 |
| 2024-11-28 | 5.77 |
| 2024-11-27 | 5.82 |
| 2024-11-26 | 5.84 |
| 2024-11-25 | 5.87 |
| 2024-11-22 | 5.80 |
| 2024-11-21 | 5.62 |
| 2024-11-20 | 5.56 |
| 2024-11-19 | 5.54 |
| 2024-11-18 | 5.49 |
| 2024-11-15 | 5.49 |
| 2024-11-14 | 5.44 |
| 2024-11-13 | 5.47 |
| 2024-11-12 | 5.51 |
| 2024-11-11 | 5.54 |
| 2024-11-08 | 5.52 |
| 2024-11-07 | 5.45 |
| 2024-11-06 | 5.38 |
| 2024-11-05 | 5.50 |
| 2024-11-04 | 5.58 |
| 2024-11-01 | 5.62 |
| 2024-10-31 | 5.58 |
| 2024-10-30 | 5.69 |
| 2024-10-29 | 5.73 |
| 2024-10-28 | 5.76 |
| 2024-10-25 | 5.78 |
| 2024-10-24 | 5.80 |
| 2024-10-23 | 5.86 |
| 2024-10-22 | 5.93 |
| 2024-10-21 | 5.91 |
| 2024-10-18 | 5.92 |
| 2024-10-17 | 5.96 |
| 2024-10-16 | 5.93 |
| 2024-10-15 | 5.83 |
| 2024-10-14 | 5.74 |
| 2024-10-11 | 5.68 |
| 2024-10-10 | 5.67 |
| 2024-10-09 | 5.70 |
| 2024-10-08 | 5.69 |
| 2024-10-07 | 5.64 |